Ken Griffin Edwards Lifesciences Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$59.7 - $93.78 $12.3 Million - $19.3 Million	206,000 Added 43.29%	681,900 $45 Million
Q2 2024 Aug 14, 2024	SELL	$84.3 - $94.31 $9.8 Million - $11 Million	-116,200 Reduced 19.63%	475,900 $44 Million
Q1 2024 May 15, 2024	SELL	$72.54 - $95.56 $12.6 Million - $16.6 Million	-173,700 Reduced 22.68%	592,100 $56.6 Million
Q4 2023 Feb 14, 2024	BUY	$61.71 - $77.76 $18.7 Million - $23.6 Million	303,700 Added 65.72%	765,800 $58.4 Million
Q3 2023 Nov 14, 2023	BUY	$69.28 - $93.38 $2.47 Million - $3.32 Million	35,600 Added 8.35%	462,100 $32 Million
Q2 2023 Aug 14, 2023	SELL	$81.41 - $94.33 $17.3 Million - $20.1 Million	-212,900 Reduced 33.3%	426,500 $40.2 Million
Q1 2023 May 15, 2023	SELL	$74.26 - $84.51 $3.18 Million - $3.62 Million	-42,800 Reduced 6.27%	639,400 $52.9 Million
Q4 2022 Feb 14, 2023	BUY	$68.3 - $87.44 $8.17 Million - $10.5 Million	119,600 Added 21.26%	682,200 $50.9 Million
Q3 2022 Nov 14, 2022	BUY	$82.37 - $107.29 $6.85 Million - $8.93 Million	83,200 Added 17.36%	562,600 $46.5 Million

1,350

457M

9.76M

3.92M

Ticker EW
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 618,259,968
Market Cap $46.3B
Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.